Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Citalopram hydrobromide
Rivopharm (UK) Ltd
N06AB04
Citalopram hydrobromide
20mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04030300; GTIN: 5060388650254
PACKAGE LEAFLET: INFORMATION FOR THE USER CITALOPRAM 10MG, 20MG & 40MG TABLETS Citalopram hydrobromide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU • Citalopram Tablets treat depression and anxiety disorders but they will not work straight away. Like all medicines, it can have side-effects. It is important that you and your doctor talk about the benefits and the possible unwanted effects of the medicine before you start taking it. • Citalopram Tablets must be taken with care by children or teenagers under 18. (See Section 2 on page 3). • Citalopram Tablets will not work straight away. You may feel worse before feeling better after starting the medicine. Your doctor should ask to see you again 2 or 3 weeks after you first start taking the medicine. Tell your doctor if you feel no better. (See Section 3 on page 5). • Some people with depression or anxiety think of harming or killing themselves. If you have any of these thoughts, see your doctor or go to a hospital straight away. (See Section 2 on page2). • If you feel restless or feel like you cannot keep still, go to your doctor. If you keep on taking more Citalopram Tablets each day, it may make these feelings worse. (See Section 4 on page 6). • Talk to your doctor before you stop taking Citalopram Tablets. If you stop taking it suddenly or miss a dose you may get unwanted effects. (See Section 4 on page 6). • Taking some other medicines with Citalopram Tablets can cause problems. You may need to talk to your doctor first. (See Section 2 on page 2). • If you are pregnant or planning to get pregnant, talk to your doctor before taking Citalopram Tablets. (See Section 2 on page 2). Keep this leaflet. You may need to read it again. If you have further questions, please ask your doctor or pharmacist or nurse. This medicine has been prescribed for you. Do not pass it to others. It may harm them, even if their sign of illness are the same as yours. If you get any of the side ef Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Citalopram 20mg Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 24.98mg of Citalopram hydrobromide equivalent to 20mg of Citalopram. For full list of excipients, see 6.1 3 PHARMACEUTICAL FORM Film coated tablets. Oval, biconvex, white colour, film coated tablets, scored on one side and with marking 20 on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For treatment of depressive illness in the initial phase and as maintenance against potential relapse/recurrence. Citalopram is also indicated in the treatment of panic disorder with or without agoraphobia. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Depression Adults: Citalopram should be administered as a single oral dose of 20 mg daily. Dependent on individual patient response, the dose may be increased to a maximum of 40 mg daily. _ _ In general improvement in patients starts after one week but may only become evident from the second week of therapy. As with all antidepressant medicinal products, dosage should be reviewed and adjusted if necessary within 3 to 4 weeks of initiation of therapy and thereafter as judged clinically appropriate. Dosage adjustments should be made carefully on an individual patient basis, to maintain the patient at the lowest effective dose. Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms. PANIC DISORDER Adults: A single oral dose of 10 mg is recommended for the first week before increasing the dose to 20 mg daily. Dependent on individual patient response, the dose may be increased to a maximum of 40 mg daily. A low initial starting dose is recommended to minimise the potential worsening of panic symptoms, which is generally recognised to occur early in the treatment of this disorder. Dosage adjustments should be made carefully on an individual patient basis, to maintain the patients at the lowest effective dose. _ _ Patients with panic Read the complete document